Current topics in CAR T-cell therapy

Webinars & Tutorials

Visit page
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

Duration 18 mins 28 secs

During this discussion, Canadian CAR T experts review pivotal trial and current real-world evidence supporting use of CAR T cell for patients with large B-cell lymphoma (LBCL), with a focus on treatment in the second-line (2L) setting. Experts also discuss key clinical and practical considerations for all stages of the 2L CAR T journey, including synergies between referral and treatment centres.

Click here to evaluate this content

View
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 2: 2L CAR T for Primary Refractory LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 2: 2L CAR T for Primary Refractory LBCL

Duration 13 mins 13 secs

In this video, Canadian CAR T experts review a clinical case of primary refractory LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with primary refractory LBCL, including patient eligibility and preparation.

Click here to evaluate this content

View
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 3: 2L CART for Primary Progressive LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 3: 2L CART for Primary Progressive LBCL

Duration 16 mins 3 secs

In this video, Canadian CAR T experts review a clinical case of primary progressive LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with primary progressive LBCL, including the role of holding/bridging therapy and the importance of quick communication between referral and treatment centres.

Click here to evaluate this content

View
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 4: 2L CART for early relapsed (<12 months) LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 4: 2L CART for early relapsed (<12 months) LBCL

Duration 17 mins 34 secs

In this video, Canadian CAR T experts review a clinical case of early relapsed (<12 months) LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with early relapsed (<12 months) LBCL, including the importance of re-biopsy and of referral and treatment centres partnership.

Click here to evaluate this content

View
Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Duration 32 mins 14 secs

In this video, Dr. Herbaux highlights emerging data and discusses his experience on the management of patients with R/R MCL. Specifically, he reviews clinical data and real-world evidence for CAR T therapy in R/R MCL, shares best-practices on patient identification, disease monitoring and management prior to CAR T infusion as well as long-term patient care post-infusion.

Click here to evaluate this content

View

Congress Symposia

Visit page
Choosing CAR T with Curative Intent

Choosing CAR T with Curative Intent

Duration 15 mins 55 secs

As part of Kite’s symposia at EHA 2024 entitled “Follow the patient pathway to survival in 2L DLBCL”, Dr. Kekre of The Ottawa Hospital reviews clinical trial data and real-world evidence for CAR T in 2L DLBCL, highlighting the importance of early referral.

Click here to evaluate this content

View
Improving Survival Outcomes: Incorporating CAR T Therapy Earlier into a Patient’s Journey with Aggressive Lymphoma - Part 1

Improving Survival Outcomes: Incorporating CAR T Therapy Earlier into a Patient’s Journey with Aggressive Lymphoma - Part 1

Duration 24 mins 9 secs

These are recordings of Kite’s symposia at CTTC 2024 entitled “Improving Survival Outcomes: Incorporating CAR T Therapy Earlier Into A Patient’s Journey With Aggressive Lymphoma”. In Part 1, Dr. Natasha Kekre discusses the evolution of Canadian experience with CAR T cell therapy for R/R LBC and how 2L CAR T may transpire in the coming year. In Part 2, Dr. David Milkos shares his experience incorporating CAR T therapy as second-line treatment and post-CAR T considerations. 

Click here to evaluate this content

View
Improving Survival Outcomes: Incorporating CAR T Therapy Earlier into a Patient’s Journey with Aggressive Lymphoma - Part 2

Improving Survival Outcomes: Incorporating CAR T Therapy Earlier into a Patient’s Journey with Aggressive Lymphoma - Part 2

Duration 16 mins 43 secs

These are recordings of Kite’s symposia at CTTC 2024 entitled “Improving Survival Outcomes: Incorporating CAR T Therapy Earlier Into A Patient’s Journey With Aggressive Lymphoma”. In Part 1, Dr. Natasha Kekre discusses the evolution of Canadian experience with CAR T cell therapy for R/R LBC and how 2L CAR T may transpire in the coming year. In Part 2, Dr. David Milkos shares his experience incorporating CAR T therapy as second-line treatment and post-CAR T considerations. 

Click here to evaluate this content

View
The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

Duration 25 mins 19 secs

These are recordings of Kite’s symposia at CANO 2023 entitled “The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma”. In this 3-part series, speakers from CAR T treatment centres across Canada will discuss the role of nurses in a patient’s path to CAR T therapy and post-treatment care with R/R LBCL. They will also share best practices on patient management and co-ordination of patient care between nurses at referral and CAR T centres.  In Part 1, Laurie Ann Holmes provides an overview of the CAR T journey, while Giselle Wilson discusses nursing care prior to cell collection. In Part 2, Cheryl Page reviews nursing considerations around CAR T administration. Finally in Part 3, Rachel Nielsen wraps up the session with the topic of nursing care post-CAR T infusion, including long term follow-up and shared care. A brief panel discussion concludes the session.

Click here to evaluate this content

View
The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 2

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 2

Duration 19 mins 47 secs

These are recordings of Kite’s symposia at CANO 2023 entitled “The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma”. In this 3-part series, speakers from CAR T treatment centres across Canada will discuss the role of nurses in a patient’s path to CAR T therapy and post-treatment care with R/R LBCL. They will also share best practices on patient management and co-ordination of patient care between nurses at referral and CAR T centres.  In Part 1, Laurie Ann Holmes provides an overview of the CAR T journey, while Giselle Wilson discusses nursing care prior to cell collection. In Part 2, Cheryl Page reviews nursing considerations around CAR T administration. Finally in Part 3, Rachel Nielsen wraps up the session with the topic of nursing care post-CAR T infusion, including long term follow-up and shared care. A brief panel discussion concludes the session.

Click here to evaluate this content

View
The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 3

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 3

Duration 18 mins 4 secs

These are recordings of Kite’s symposia at CANO 2023 entitled “The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma”. In this 3-part series, speakers from CAR T treatment centres across Canada will discuss the role of nurses in a patient’s path to CAR T therapy and post-treatment care with R/R LBCL. They will also share best practices on patient management and co-ordination of patient care between nurses at referral and CAR T centres.  In Part 1, Laurie Ann Holmes provides an overview of the CAR T journey, while Giselle Wilson discusses nursing care prior to cell collection. In Part 2, Cheryl Page reviews nursing considerations around CAR T administration. Finally in Part 3, Rachel Nielsen wraps up the session with the topic of nursing care post-CAR T infusion, including long term follow-up and shared care. A brief panel discussion concludes the session.

Click here to evaluate this content

View
Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Duration 27 mins 21 secs

As part of Kite’s symposia at EHA 2023 entitled “Managing R/R Adult ALL in the CAR T Era”, Dr. Shah and Dr. Rabian discuss CAR T treatment approaches in R/R adult ALL, including clinical trial and real-world data updates, as well as present real patient cases.

Click here to evaluate this content

View